The startups betting you can quit glr-1s and stay thin.

The article discusses the move of startups in the weight-loss industry, such as Calibrate and Noom, to market glucagon-like peptide-1 (GLP-1) as temporary treatments for weight loss that offer long-term effects. Topics covered include the reason why investors see the GLP-1 market as one prime for scale, the assertion by manufacturers of GLP-1s that the medicines are not meant to be taken only temporarily and Calibrate's strategy and model for marketing GLP-1.